Methylation of RASSF1A and CDH13 Genes in Individualized Chemotherapy for Patients with Non-small Cell Lung Cancer

Xu, Zuhua; Li, Shijun

doi:10.7314/apjcp.2014.15.12.4925

Cited by 24 publications

(19 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CDH13 is a cell adherence protein of a unique cadherin superfamily member and functions to mediate intracellular signaling in vascular cells. Emerging evidence indicates that CDH13 is a candidate tumor suppressor in several types of human cancer, including breast and lung cancer (12,(20)(21)(22)(23)(24)(25)(26), colorectal cancer (21,27), hepatocellular carcinoma (28), bladder cancer (29), cervical cancer (30) and ovarian cancer (31)(32)(33)(34). Previous studies have showed that CDH13 promoter methylation is a frequent event in cancer, which is associated with unfavorable tumor features, increased risk of recurrence and poorer survival rates, and has been suggested as an independent predictor for tumor recurrence and progression (26,29).…”

Section: Dkk3 (M) Cdh13 (M) Foxl2 (M) Ezh2 (M) ----------------------mentioning

confidence: 99%

Hypermethylation of CDH13, DKK3 and FOXL2 promoters and the expression of EZH2 in ovary granulosa cell tumors

Wang

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

Aberrant epigenetic modification is associated with the development and progression of cancer. Hypermethylation of tumor suppressor gene promoters and cooperative histone modification have been considered to be the primary mechanisms of epigenetic modification. Ovary granulosa cell tumors (GCTs) are relatively rare, accounting for ~3% of all ovarian malignancies. The present study assessed hypermethylation of the cadherin 13 (CDH13), dickkopf WNT signaling pathway inhibitor 3 (DKK3) and forkhead box L2 (FOXL2) promoters in 30 GCT tissues and 30 healthy control tissues using methylation-specific polymerase chain reaction analysis. The data showed that the frequencies of CDH13, DKK3 and FOXL2 promoter methylation were significantly higher in the GCT tissues, compared with the healthy control tissues (86.67, vs. 23.33%; 80, vs. 26.67% and 66.67, vs. 20%, respectively; P<0.001). Immunostaining of enhancer of zeste homolog 2 (EZH2), a histone H3K27 methyltransferase, showed that the EZH2 protein was expressed in 11 of the 30 GCT tissue samples, whereas no EZH2 protein was expressed in the 30 healthy control tissues (P<0.01). These data suggested that hypermethylation of the CDH13, DKK3 and FOXL2 gene promoters, and overexpression of the EZH2 protein were involved in the development of GCT.

show abstract

Section: Dkk3 (M) Cdh13 (M) Foxl2 (M) Ezh2 (M) ----------------------mentioning

confidence: 99%

Hypermethylation of CDH13, DKK3 and FOXL2 promoters and the expression of EZH2 in ovary granulosa cell tumors

Wang

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…Epigenetic inactivation of RASSF1A by hyper-methylation of its promoter region was originally identified in patients with various types of cancer. RASSF1A inactivation has been reported in bladder, breast, lung, colorectal, and prostate cancers, among others (Abouzeid et al, 2011;Sebova et al, 2011Sebova et al, -2012Yaqinuddin et al, 2013;Bilgrami et al, 2014;Zhai and Li, 2014). While RASSF1A inactivation by promoter methylation is known to perform an important function in tumorigenesis, its specific action in renal cancer has neither been thoroughly investigated nor reviewed.…”

Section: Introductionmentioning

confidence: 99%

Association between RASSF1A promoter methylation and renal cell cancer susceptibility: a meta-analysis

et al. 2016

View full text Add to dashboard Cite

ABSTRACT. Epigenetic inactivation of Ras-associated domain family 1A (RASSF1A) by hyper-methylation of its promoter region has been identified in various cancers. However, the role of RASSF1A in renal cancer has neither been thoroughly investigated nor reviewed. In this study, we reviewed and performed a meta-analysis of 13 published studies reporting correlations between methylation frequency of the RASSF1A promoter region and renal cancer risk. The odds ratios (ORs) of eligible studies and their corresponding 95% confidence intervals (95%CIs) were used to correlate RASSF1A promoter methylation with renal cell cancer risk and clinical or pathological variables, respectively. RASSF1A promoter methylation was significantly associated with the risk of renal cell cancer (OR = 19.35, 95%CI = 9.57-39.13). RASSF1A promoter methylation was significantly associated with pathological tumor grade (OR = 3.32, 95%CI = 1.55-7.12), and a possible positive correlation between RASSF1A promoter methylation status and tumor stage was noted (OR = 1.89, 95%CI = 1.00-3.56, P = 0.051). Overall, this meta-analysis demonstrated that RASSF1A promoter methylation is significantly associated with increased risk of renal cell cancer. RASSF1A promoter methylation frequency was positively correlated with pathological tumor grade, but not the clinical stage. This study showed that RASSF1A promoter methylation could be utilized to predict renal cell cancer prognosis.

show abstract

“…8,27 The methylation of these genes has good sensitivity and specificity in lung cancer. 23,28 Our results showed that there were significant differences in the methylation levels of the 8 genes between lung cancer patients and non-lung cancer patients. Methylation of RASSF1A, CDKN2A and DLEC1 occurred only in lung cancer patients, while the methylation of CALCA, CDH13, PITX2, HOXA9, and WT1 occurred not only in lung cancer patients, but also in non-lung cancer patients.…”

Section: Discussionmentioning

confidence: 63%

“…The reason for its nonexpression may be the specific methylation of CpG island in the promoter region. 23 DLEC1 is a tumor suppressor gene located at the 3p21.3 region. It can inhibit the growth of lung cancer, esophageal cancer and the renal carcinoma cell line.…”

Section: Discussionmentioning

confidence: 99%

DNA methylation analysis of selected genes for the detection of early-stage lung cancer using circulating cell-free DNA

Yang¹,

Qi²,

Sun³

et al. 2018

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

Methylation of RASSF1A and CDH13 Genes in Individualized Chemotherapy for Patients with Non-small Cell Lung Cancer

Cited by 24 publications

References 12 publications

Hypermethylation of CDH13, DKK3 and FOXL2 promoters and the expression of EZH2 in ovary granulosa cell tumors

Hypermethylation of CDH13, DKK3 and FOXL2 promoters and the expression of EZH2 in ovary granulosa cell tumors

Association between RASSF1A promoter methylation and renal cell cancer susceptibility: a meta-analysis

DNA methylation analysis of selected genes for the detection of early-stage lung cancer using circulating cell-free DNA

Contact Info

Product

Resources

About